AnaMar is a privately held, clinical-stage biotech company developing a first-in-class, orally bioavailable, peripheral-acting 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine.
AM1476 is a highly selective small molecule, which offers a unique dual-action potential to treat skin and lung manifestations of systemic sclerosis with a favorable safety profile.
AnaMar has positive results from its Phase I study. AM1476 was safe and well-tolerated in a trial of around 100 healthy volunteers.
We have completed Phase II enabling pre-clinical studies for the initial orphan indication systemic sclerosis.
We are combining our innovative therapeutic platform with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, using our heritage in diagnostics to ensuring the best outcomes for those with fibrosis.